Disproportionate Visceral Fat Reduction Tirzepatide reduces visceral adipose tissue beyond what total weight loss data would predict a metabolically significant effect because VAT is the primary driver of insulin resistance, cardiometabolic risk, and the inflammatory burden of obesity
This combination increased miR-34a in CRC cell lines and tumor tissue (Nobari et al., 2023)
[2]National Institute for Health and Care Excellence, Semaglutide for Managing Overweight and Obesity, nice.org.uk Novo Nordisk is currently testing 25 mg and 50 mg oral doses to close the efficacy gap without injections, with Phase III readouts expected in late 2026
Eating smaller meals may help
Type 2 diabetes explained Type 2 diabetes is a condition in which the cells in your body become resistant to the effects of a hormone called insulin
It helps regulate appetite and food intake